ADMA Biologics (ADMA) to Release Quarterly Earnings on Wednesday

ADMA Biologics (NASDAQ:ADMA) is anticipated to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect ADMA Biologics to announce earnings of $0.1633 per share and revenue of $125.3440 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.19. The business had revenue of $114.49 million during the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.ADMA Biologics’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.11 earnings per share. On average, analysts expect ADMA Biologics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Stock Performance

Shares of ADMA opened at $8.74 on Tuesday. The business has a 50-day simple moving average of $8.51 and a two-hundred day simple moving average of $11.49. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $20.46. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of 12.85 and a beta of 0.74.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ADMA shares. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Canaccord Genuity Group decreased their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Mizuho dropped their price target on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Finally, Zacks Research raised shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Three equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, ADMA Biologics presently has an average rating of “Moderate Buy” and an average target price of $18.67.

ADMA Biologics News Summary

Here are the key news stories impacting ADMA Biologics this week:

• Neutral Sentiment: Multiple law firms reminded shareholders that August 10, 2026 is the deadline to seek appointment as lead plaintiff. The notices generally cover investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. Rosen Law Firm deadline notice
• Negative Sentiment: The filed lawsuit alleges that ADMA made materially false or misleading statements about its financial condition, revenue recognition, inventory distribution and business practices. Hagens Berman class action alert
• Negative Sentiment: Specific allegations include channel stuffing to create the appearance of revenue, an undisclosed related-party transaction and inadequate internal controls. If proven, these claims could lead to financial liability, additional disclosure requirements and reputational damage. Holzer & Holzer class action notice
• Negative Sentiment: The unusually large number of substantially similar law-firm announcements may amplify investor attention to the allegations, even though the claims remain unproven and the notices primarily seek additional plaintiffs rather than announcing a new judgment against ADMA. Bragar Eagel & Squire deadline reminder

Insider Activity

In other news, Director Jerrold B. Grossman bought 12,500 shares of ADMA Biologics stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $8.01 per share, with a total value of $100,125.00. Following the completion of the acquisition, the director owned 513,884 shares of the company’s stock, valued at $4,116,210.84. This trade represents a 2.49% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

Several institutional investors have recently added to or reduced their stakes in ADMA. Summit Securities Group LLC purchased a new stake in shares of ADMA Biologics during the 4th quarter worth approximately $29,000. iSAM Funds UK Ltd bought a new position in shares of ADMA Biologics during the 3rd quarter valued at approximately $34,000. EverSource Wealth Advisors LLC grew its holdings in shares of ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 2,180 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of ADMA Biologics by 28.9% in the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 700 shares in the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in ADMA Biologics in the fourth quarter worth $72,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.